Professor Wang Jie: Precision Treatment for Lung Cancer
Professor Wang Jie is a senior medical oncologist, professor, and doctoral supervisor at Peking University Cancer Hospital. Her clinical and academic work focuses on lung cancer, molecular diagnosis, targeted therapy, immunotherapy, treatment resistance, and biomarker-guided clinical trials.
International patients can learn more about the hospital, pathology requirements, and treatment planning in our Peking University Cancer Hospital international patient guide.
Clinical Specialties
- non-small cell lung cancer;
- lung adenocarcinoma and squamous-cell carcinoma;
- small-cell lung cancer;
- molecular testing and liquid biopsy;
- targeted therapy for actionable driver alterations;
- immune checkpoint therapy;
- treatment after acquired resistance;
- brain and other distant metastases; and
- clinical-trial evaluation.
Non-Small Cell Lung Cancer
Non-small cell lung cancer accounts for most lung cancers and includes several biological subtypes. Treatment depends on stage, pathology, molecular findings, PD-L1 expression, symptoms, organ function, and previous therapy.
Early-stage disease may be treated with surgery, radiotherapy, systemic therapy, or a planned combination. Locally advanced and metastatic disease usually requires multidisciplinary assessment and biomarker-guided systemic treatment.
Molecular Testing
For advanced non-squamous non-small cell lung cancer, testing may include EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, HER2, and other clinically relevant alterations. Testing requirements vary by pathology and treatment setting.
A tissue sample is generally preferred when available because it confirms diagnosis and supports broad testing. Blood-based liquid biopsy can be useful when tissue is limited or when resistance develops, but a negative blood result does not always exclude a tumor alteration.
Targeted Therapy
Targeted medicines can produce substantial benefit when a tumor contains a matching actionable alteration. The treatment sequence depends on the gene, exact variant, stage, previous medicines, brain involvement, side effects, and approved options.
Resistance eventually develops in many advanced cancers. Repeat tissue or blood testing may identify a new mechanism and guide another targeted medicine, chemotherapy, local treatment, or a clinical trial.
Immunotherapy
Immune checkpoint inhibitors may be used alone or with chemotherapy for selected lung cancers. PD-L1 can help guide treatment, but it is not the only factor. Driver alterations, autoimmune disease, transplant history, tumor burden, and urgency of response also matter.
Immune-related side effects can affect the lungs, liver, bowel, endocrine glands, skin, heart, nervous system, and other organs. New breathing difficulty, diarrhea, jaundice, severe weakness, chest pain, or hormonal symptoms requires prompt medical review.
Brain Metastases
Lung cancer can spread to the brain. Treatment may include a brain-penetrating targeted medicine, stereotactic radiosurgery, surgery, whole-brain radiotherapy, immunotherapy, chemotherapy, or a combination.
The plan depends on symptoms, number and size of lesions, molecular subtype, extracranial disease, and previous treatment. New weakness, seizure, severe headache, confusion, or speech difficulty requires urgent local care.
Small-Cell Lung Cancer
Small-cell lung cancer usually grows rapidly and is commonly treated with chemotherapy, immunotherapy in selected settings, and radiotherapy. Treatment differs according to limited-stage or extensive-stage disease and the patient’s condition.
Who May Consider a Consultation?
- patients with newly diagnosed advanced lung cancer;
- patients needing pathology or molecular re-review;
- patients with an actionable driver alteration;
- patients whose cancer progressed after targeted therapy or immunotherapy;
- patients with brain or other complex metastases;
- patients with conflicting recommendations about treatment sequence;
- patients considering repeat biopsy or liquid biopsy; or
- patients assessing clinical-trial options.
Medical Records to Prepare
- a concise medical summary and exact treatment timeline;
- chest CT, PET-CT, brain MRI, and other imaging in original DICOM format;
- pathology reports, glass slides, and paraffin blocks;
- complete molecular, liquid-biopsy, and PD-L1 reports;
- operative and radiotherapy records;
- every systemic treatment with dates, doses, response, and toxicity;
- recent blood count, liver and kidney function, and relevant cardiac tests;
- current symptoms and performance status; and
- a clear list of treatment priorities and questions.
Planning an International Consultation
Before traveling, patients should confirm whether records, imaging, pathology, and molecular results can be reviewed. Remote medical-record review is subject to physician authorization, and final treatment or clinical-trial eligibility requires complete specialist assessment.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating oncology records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor Wang, remote review, a particular medicine, or a clinical trial is subject to the doctor’s and hospital’s approval. CMCS does not guarantee appointments, treatment eligibility, trial enrollment, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor roles, biomarker requirements, medicine approvals, trial availability, and appointment arrangements may change. This profile is for general information only and does not replace assessment by a qualified thoracic oncology team.
0 Kommentare